Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
Authors:
Open Access
- 28 February 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 17 (3) , 603-613
Abstract
Chordomas are rare bone tumors with no approved therapy. These tumors express several activated tyrosine kinase receptors, which prompted attempts to treat patients with tyrosine kinase inhibitors. Although clinical benefit was observed in phase II clinical trials with imatinib and sorafenib, and sporadically also with EGFR inhibitors, therapies evaluated to date have shown modest activity. With the goal of identifying new drugs with immediate therapeutic potential for chordoma patients, we collected clinically approved drugs and other advanced inhibitors of MET, PDGFRβ, and EGFR tyrosine kinases, and assessed their antiproliferative activity against a panel of chordoma cell lines. Chordoma cell lines were not responsive to MET and PDGFRβ inhibitors. U-CH1 and UM-Chor1 were sensitive to all EGFR inhibitors, whereas the remaining cell lines were generally insensitive to these drugs. Afatinib was the only EGFR inhibitor with activity across the chordoma panel. We then investigated the molecular mechanisms behind the responses observed and found that the antiproliferative IC50s correlate with the unique ability of afatinib to promote degradation of EGFR and brachyury, an embryonic transcription factor considered a key driver of chordoma. Afatinib displayed potent antitumor efficacy in U-CH1, SF8894, CF322, and CF365 chordoma tumor models in vivo. In the panel analyzed, high EGFR phosphorylation and low AXL and STK33 expression correlated with higher sensitivity to afatinib and deserve further investigation as potential biomarkers of response. These data support the use of afatinib in clinical trials and provide the rationale for the upcoming European phase II study on afatinib in advanced chordoma. Mol Cancer Ther; 17(3); 603–13. ©2017 AACR.Keywords
All Related Versions
This publication has 53 references indexed in Scilit:
- Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PETJournal of Nuclear Medicine, 2013
- From Notochord Formation to Hereditary Chordoma: The Many Roles ofBrachyuryBioMed Research International, 2013
- Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature reviewBMC Cancer, 2011
- Frequent activation of EGFR in advanced chordomasClinical Sarcoma Research, 2011
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet CancerCancer Research, 2011
- Molecular Characterization of Putative Chordoma Cell LinesSarcoma, 2010
- Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasNeuro-Oncology, 2010
- T (brachyury) gene duplication confers major susceptibility to familial chordomaNature Genetics, 2009
- Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsCancer Research, 2009
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008